OverviewSuggest Edit

Abliva (formerly NeuroVive Pharmaceutical) is a company engaged in the research and development of mitochondrial medicine. Its product portfolio includes NeuroSTAT, a drug candidate for the treatment of traumatic brain injuries; and ToxPhos for the mitochondrial toxicity test. The Company is also developing drugs for mitochondrial genetic disorders, mitochondrial myopathies and hepatocellular carcinoma. It has collaboration agreements with several pharmaceutical companies, and a preclinical collaboration agreement with a hospital for research in mitochondrial medicine field.

TypePublic
Founded1998
HQLund, SE
Websiteabliva.com

Latest Updates

Employees (est.) (May 2021)9
Share Price (Jun 2021)KR0.7
Cybersecurity ratingAMore

Key People/Management at Abliva

David Laskow-Pooley

David Laskow-Pooley

Chairman
David Bejker

David Bejker

Board Member
Jan Törnell

Jan Törnell

Board Member
Denise Goode

Denise Goode

Board Member
Catharina Jz Johansson

Catharina Jz Johansson

CFO & Vice President Investor Relations
Eskil Elmér

Eskil Elmér

CSO & Vice President Discovery
Show more

Abliva Office Locations

Abliva has an office in Lund
Lund, SE (HQ)
Medicon Village
Show all (1)

Abliva Financials and Metrics

Abliva Revenue

Market capitalization (7-Jun-2021)

243.4m

Closing stock price (7-Jun-2021)

0.7
Abliva's current market capitalization is kr243.4 m.
Show all financial metrics

Abliva Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Abliva Online and Social Media Presence

Embed Graph

Abliva News and Updates

NeuroVive Pharmaceutical AB Year End Report January - December 2019

STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVive completes recruitment of healthy volunteers...

NeuroVive Pharmaceutical AB Interim Report January - September 2019

STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter...

NeuroVive Pharmaceutical AB Interim Report January - June 2019

STOCKHOLM, Aug. 21, 2019 /PRNewswire/ -- Important events April – June The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. The Supreme Court delivers its...

NeuroVive Pharmaceutical AB Publishes 2018 Annual Report

LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website www.neurovive.com. This information is information that NeuroVive...

Abliva Blogs

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2021 held its Annual General Meeting (“AGM”). Due to the continued spread of the coronavirus and the authorities’ regulations/advice on avoiding public gatherings, the Annual General Meeting was conducted only by postal …

Abliva AB Interim Report January – March 2021

First quarter summary

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced positive safety and pharmacokinetic data from the double-blind, randomized, placebo-controlled Phase 1a/b stu…

Abliva publishes prospectus and new information contained in the prospectus

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the prospectus that Abliva has prepared regarding admission to trading of 74,065,3…

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announce that the number of shares and votes in the Company has increased by 32,601,360 as a result of a directed new issue of shares resolved by the Board of Directors on 30 March 2021 with authorization from the Annual General Meeting held on 20 May 2020.

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities’ regulations/advice on avoiding public gatherings, the Extraordinary General Meeting was conducted only by postal vote an…
Show more

Abliva Frequently Asked Questions

  • When was Abliva founded?

    Abliva was founded in 1998.

  • Who are Abliva key executives?

    Abliva's key executives are David Laskow-Pooley, David Bejker and Jan Törnell.

  • How many employees does Abliva have?

    Abliva has 9 employees.

  • Who are Abliva competitors?

    Competitors of Abliva include ViewPoint Therapeutics, Acousia Therapeutics and Nordic Nanovector.

  • Where is Abliva headquarters?

    Abliva headquarters is located at Medicon Village, Lund.

  • Where are Abliva offices?

    Abliva has an office in Lund.

  • How many offices does Abliva have?

    Abliva has 1 office.